Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to continue its efforts to broaden the covalent drug alphabet. | Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to continue its efforts to broaden the covalent drug alphabet.

Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors. * April 15, 2026 Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to continue its efforts to broaden the covalent drug alphabet. Fields (*) Mark are Required

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development.“The most important predicter of successful drug development is a team of people who have successfully developed a therapy from discovery to regulatory approval,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto. “I am honored to once again be working alongside Jamie on compelling science and an innovative approach to developing groundbreaking medicines with the goal of changing the treatment paradigm for people with devastating diseases. His addition to the leadership team positions Terremoto to execute on our mission and deliver much needed treatments to patients.”Terremoto’s Board chairperson, Peter Thompson, M.D., added, “Jamie has provided exceptional guidance and expertise as one of our scientific advisors, and I am thrilled for him to join the leadership team at such a pivotal moment in the company’s growth. His extensive experience in precision oncology drug development and proven track record in advancing high-impact medicines from discovery through regulatory approval aligns perfectly with our goal to discover and develop novel therapies for patients in need.”Terremoto is harnessing the power of an exceptional chemistry team and expanded covalent alphabet to create highly targeted therapeutics for a variety of severe diseases. The company is applying its unique capabilities to develop differentiated best-in-class therapies against established drug targets and first-in-class medicines against high-value, previously undrugged targets in oncology and beyond.“The outstanding team at Terremoto has already built the foundation for innovative drug development and delivered on high-quality development candidates, providing an immense opportunity to be on the cutting edge of targeted oncology and addressing other unmet medical needs,” said Dr. Christensen